Literature DB >> 20123465

The role of intelligence in phenylketonuria: a review of research and management.

V L Brumm1, M L Grant.   

Abstract

Phenylketonuria (PKU) results in profound intellectual disability in untreated individuals and more subtle cognitive deficits in individuals treated early and continuously. The assessment of intellectual functioning has been an important outcome variable and the focus of extensive research. Since the implementation of neonatal PKU screening programs in the 1960s, research on intellectual functioning in individuals with PKU has played a significant and positive role in guiding therapy and improving results. This is a literature review examining the relationship between intellectual outcome and treatment parameters including initiation of treatment, duration of treatment, and blood phenylalanine (Phe) levels from infancy through adulthood. While current PKU treatment practices have eliminated severe neurological and cognitive impairment, evidence suggests that intellectual functioning, although typically within the average range when PKU is treated early and continuously, may not be maximized under the current definition of well-controlled PKU, which is based on blood Phe levels. Future research assessing intellectual and neurocognitive outcome in PKU will enhance the development of new treatment strategies. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20123465     DOI: 10.1016/j.ymgme.2009.10.015

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  13 in total

1.  Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria.

Authors:  Oriane Leuret; Magalie Barth; Alice Kuster; Didier Eyer; Loïc de Parscau; Sylvie Odent; Brigitte Gilbert-Dussardier; François Feillet; François Labarthe
Journal:  J Inherit Metab Dis       Date:  2012-03-03       Impact factor: 4.982

2.  Decreased functional brain connectivity in individuals with early-treated phenylketonuria: evidence from resting state fMRI.

Authors:  Shawn E Christ; Amanda J Moffitt; Dawn Peck; Desirée A White; Joseph Hilgard
Journal:  J Inherit Metab Dis       Date:  2012-01-10       Impact factor: 4.982

3.  Tract-based evaluation of white matter damage in individuals with early-treated phenylketonuria.

Authors:  Huiling Peng; Dawn Peck; Desirée A White; Shawn E Christ
Journal:  J Inherit Metab Dis       Date:  2013-09-17       Impact factor: 4.982

4.  Prolonged exposure to high and variable phenylalanine levels over the lifetime predicts brain white matter integrity in children with phenylketonuria.

Authors:  Anna Hood; Jo Ann V Antenor-Dorsey; Jerrel Rutlin; Tamara Hershey; Joshua S Shimony; Robert C McKinstry; Dorothy K Grange; Shawn E Christ; Robert Steiner; Desiree A White
Journal:  Mol Genet Metab       Date:  2014-11-13       Impact factor: 4.797

5.  White matter integrity and executive abilities in individuals with phenylketonuria.

Authors:  Jo Ann V Antenor-Dorsey; Tamara Hershey; Jerrel Rutlin; Joshua S Shimony; Robert C McKinstry; Dorothy K Grange; Shawn E Christ; Desirée A White
Journal:  Mol Genet Metab       Date:  2013-04-06       Impact factor: 4.797

6.  White matter integrity and executive abilities following treatment with tetrahydrobiopterin (BH4) in individuals with phenylketonuria.

Authors:  Desirée A White; Jo Ann V Antenor-Dorsey; Dorothy K Grange; Tamara Hershey; Jerrel Rutlin; Joshua S Shimony; Robert C McKinstry; Shawn E Christ
Journal:  Mol Genet Metab       Date:  2013-07-19       Impact factor: 4.797

7.  Processing speed and executive abilities in children with phenylketonuria.

Authors:  Alicia L Janos; Dorothy K Grange; Robert D Steiner; Desirée A White
Journal:  Neuropsychology       Date:  2012-08-06       Impact factor: 3.295

Review 8.  Caring for children with phenylketonuria.

Authors:  Linda Casey
Journal:  Can Fam Physician       Date:  2013-08       Impact factor: 3.275

9.  Neonatal screening and genotype-phenotype correlation of hyperphenylalaninemia in the Chinese population.

Authors:  Xin Wang; Yanyun Wang; Dingyuan Ma; Zhilei Zhang; Yahong Li; Peiying Yang; Yun Sun; Tao Jiang
Journal:  Orphanet J Rare Dis       Date:  2021-05-12       Impact factor: 4.123

10.  The effects of tetrahydrobiopterin (BH4) treatment on brain function in individuals with phenylketonuria.

Authors:  Shawn E Christ; Amanda J Moffitt; Dawn Peck; Desirée A White
Journal:  Neuroimage Clin       Date:  2013-08-30       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.